Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815125 | 0.82 | TSHR (0.33) | KDM1APLA2G4ALTB4R | |
| SCHEMBL4805310 | 0.81 | PTGER4 (0.35) | KDM1APLA2G4ALTB4RNR3C1PGR | |
| SCHEMBL4812944 | 0.81 | PLA2G4A (0.38) | KDM1APLA2G4ALTB4R | |
| SCHEMBL5168021 | 0.81 | PTGER4 (0.38) | KDM1APLA2G4ALTB4RNR3C1PGR | |
| SCHEMBL4805981 | 0.79 | ROCK2 (0.38) | KDM1APLA2G4ALTB4RAR | |
| SCHEMBL4812930 | 0.78 | PLA2G4A (0.41) | KDM1APLA2G4ALTB4RSLC22A12 | |
| SCHEMBL4810862 | 0.77 | SLC22A12 (0.42) | PLA2G4ALTB4RSLC22A12 | |
| SCHEMBL4815590 | 0.75 | PLAU (0.38) | SLC22A12 | |
| SCHEMBL4809827 | 0.73 | PLA2G4A (0.42) | PLA2G4ALTB4RNR3C1PGRNR3C2 | |
| SCHEMBL4815505 | 0.73 | TSHR (0.36) | KDM1APLA2G4ALTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417063-B2 | Bicyclic heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228000-A1 | of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent | F12, F11, F2 | KDM1A 405/4885PLA2G4A 271/4885LTB4R 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.